NDAORALTABLET
Approved
Nov 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALPIN 50 (anisotropine methylbromide) is an oral anticholinergic agent approved in 1962 for gastrointestinal indications. It functions as a competitive antagonist of acetylcholine at muscarinic receptors, reducing smooth muscle contractions and gastric acid secretion. This legacy product targets patients with functional gastrointestinal disorders and related conditions.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), career opportunities are limited to maintenance and defensive strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VALPIN 50 currently shows zero linked job openings, reflecting its status as a legacy maintenance product with minimal commercial momentum. Career growth on this product is constrained; roles focus on defending market share and managing decline rather than expansion or innovation.
Brand ManagerRegional Sales Manager
Worked on VALPIN 50 at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.